Briefing
LBA9 ctDNA-guided adjuvant chemotherapy de-escalation in stage III colon cancer: Primary analysis of the ctDNA-negative cohort from the randomized AGITG DYNAMIC-III trial (Intergroup study of AGITG and CCTG)
Protocol de-escalation occurred in 90.4%. Oxaliplatin-based chemotherapy use fell (34.8% vs 88.6%, P<0.001), as did grade 3+ adverse events of special interest (6.2% vs 10.6%, P=0.037) and treatment-related hospitalization (8.5% vs 13.2%, P=0.048). Non-inferiority of 3-year RFS was not confirmed (85.3% vs 88.1%; difference -2.8%; 97.5% lower CI -8.0%; NI margin 7.5%). A pre-planned subgroup of clinically low-risk T1-3N1 tumors had difference -2.2% (97.5% lower CI -7.2%), within the NI margin.
- Design: LBA
- n: 702 ctDNA-negative of 968 evaluable (72.5%); 353 ctDNA-guided, 349 standard; median follow-up 45 months
- Assay: tumor-informed (testing 5-6 weeks post-surgery; commercial name not stated in the abstract)